Mirum Pharmaceuticals Inc (MIRM)vsRegeneron Pharmaceuticals Inc (REGN)
MIRM
Mirum Pharmaceuticals Inc
$100.65
+6.94%
HEALTHCARE · Cap: $6.46B
REGN
Regeneron Pharmaceuticals Inc
$784.36
+1.59%
HEALTHCARE · Cap: $78.31B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 2627% more annual revenue ($15.53B vs $569.61M). REGN leads profitability with a 27.9% profit margin vs -140.2%. REGN earns a higher WallStSmart Score of 66/100 (B-).
MIRM
Avoid30
out of 100
Grade: F
REGN
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+46.8%
Fair Value
$187.59
Current Price
$100.65
$86.94 discount
Margin of Safety
+45.7%
Fair Value
$1415.47
Current Price
$784.36
$631.11 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 43.3% year-over-year
Strong operational efficiency at 33.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Elevated debt levels
Trading at 25.3x book value
ROE of -329.4% — below average capital efficiency
Weak financial health signals
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : MIRM
The strongest argument for MIRM centers on Revenue Growth. Revenue growth of 43.3% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 27.9% and operating margin at 33.1%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : MIRM
The primary concerns for MIRM are EPS Growth, Debt/Equity, Price/Book.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
MIRM profiles as a hypergrowth stock while REGN is a growth play — different risk/reward profiles.
MIRM carries more volatility with a beta of 0.48 — expect wider price swings.
MIRM is growing revenue faster at 43.3% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (66/100 vs 30/100), backed by strong 27.9% margins and 16.7% revenue growth. MIRM offers better value entry with a 46.8% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Mirum Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver diseases. The company is headquartered in Foster City, California.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?